BioLife SolutionsBLFS +4.25%72 Altman Z-Score is 28.60 as of Jun. 27, 2026, which is 120% above its 10-year median of 12.98. GuruFocus rates BLFS with a GF Score™ of 72/100 and a GF Value™ of $28.57 (Fairly Valued). The stock has 5 warning signs investors should review. Among 809 Medical Devices & Instruments companies, BioLife Solutions ranks better than 95.8% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 28.6 is strong.
BioLife Solutions has a Altman Z-Score of 28.60, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for BioLife Solutions's Altman Z-Score or its related term are showing as below:
BLFS'
s Altman Z-Score Range Over the Past 10 Years
Min: -11.7 Med: 12.98 Max: 75.29
Current: 28.6
During the past 13 years, BioLife Solutions's highest Altman Z-Score was 75.29. The lowest was -11.70. And the median was 12.98.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
BioLife Solutions Altman Z-Score Related Terms
BioLife Solutions Altman Z-Score Historical Data
* Premium members only.
The historical data trend for BioLife Solutions's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLFS vs KMTS, AZTA, ATRC: Altman Z-Score Comparison
For the Medical Instruments & Supplies subindustry, BioLife Solutions's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLife Solutions Altman Z-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where BioLife Solutions's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
BioLife Solutions's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.2868
+
1.4
*
-0.8444
+
3.3
*
-0.0259
+
0.6
*
48.7961
+
1.0
*
0.2489
=
28.60
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
BioLife Solutions (BLFS) has a Altman Z-Score of 28.60 as of Jun. 27, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on BioLife Solutions and its competitors. This is 120% above median its historical median of 12.98. According to the industry distribution chart, BioLife Solutions ranks #34 out of 809 companies in the Medical Devices & Instruments industry, placing it in the top 4.2%.
Is BioLife Solutions' Altman Z-Score too high?
BioLife Solutions' current Altman Z-Score of 28.60 is 120% above median its 10-year median of 12.98. The Medical Devices & Instruments industry median Altman Z-Score is 2.92. BioLife Solutions' value of 28.60 is 879.5% above this industry median. Based on the distribution chart, BioLife Solutions ranks #34 out of 809 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, BioLife Solutions has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Altman Z-Score compare to KMTS and AZTA?
According to the Medical Devices & Instruments industry distribution chart, BioLife Solutions ranks #34 out of 809 companies for Altman Z-Score. This places BioLife Solutions in the top 4% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.92. BioLife Solutions' value of 28.60 is 879.5% above this benchmark. While the company's 10-year median is 12.98 vs. the industry median of 2.92, BioLife Solutions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Devices & Instruments company?
The median Altman Z-Score among Medical Devices & Instruments companies is 2.92, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLife Solutions's current Altman Z-Score of 28.60 is 879.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on BioLife Solutions and its competitors. For the Medical Devices & Instruments industry, the median Altman Z-Score is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLife Solutions's current Altman Z-Score is 28.60, which is 120% above median its own 10-year median of 12.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Fairly Valued. The stock's GF Value™ is $28.57, compared to a current price of $28.64 — trading 0.2% above its estimated fair value. The current Altman Z-Score is 28.60, which is 120% above median its 10-year median of 12.98 and 879.5% above the Medical Devices & Instruments industry median of 2.92. BioLife Solutions' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current Altman Z-Score is 28.60 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioLife Solutions (BLFS) Overvalued in 2026?
Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued.
The current stock price of $28.64 is trading 0.2% above its estimated GF Value™ of $28.57.
GuruFocus considers BioLife Solutions to be Fairly Valued.
Key valuation signals for BLFS:
Altman Z-Score: 28.60 (120% above median its 10-year median of 12.98)
GF Value™: $28.57 vs. price of $28.64 (0.2% above fair value)
Industry Position: 879.5% above the Medical Devices & Instruments median (#34 of 809)
No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score
Get the complete analysis for BLFS
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLFS has been successfully added to your 
